Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2.

Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2.

COVID-19 is a global crisis of unimagined dimensions. Currently, Remedesivir is only fully licensed FDA therapeutic. A major target of the vaccine effort is the SARS-CoV-2 spike-hACE2 interaction, and assessment of efficacy relies on time consuming neutralization assay. Here, we developed a cell fus...

Full description

Bibliographic Details
Main Authors: Min Zhao, Pei-Yi Su, Danielle A Castro, Therese N Tripler, Yingxia Hu, Matthew Cook, Albert I Ko, Shelli F Farhadian, Benjamin Israelow, Charles S Dela Cruz, Yong Xiong, Richard E Sutton, Yale IMPACT Research Team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-06-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1009683

Internet

https://doi.org/10.1371/journal.ppat.1009683

Similar Items